[1]
Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
[2]
Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Exp Opin Drug Saf 2008; 7: 761-9.
[3]
Citrome L, Holt RI, Walker DJ, et al. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig 2011; 31: 455-82.
[4]
Bliss SA, Warnock JK. Psychiatric medications: adverse cutaneous drug reactions. Clin Dermatol 2013; 31: 101-9.
[5]
Warnock JK, Morris DW. Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol 2002; 3: 629-36.
[6]
Warnock J, Morris D. Adverse cutaneous reactions to mood stabilizers. Am J Clin Dermatol 2002; 4: 21-30.
[7]
Warnock JK, Morris DW. Adverse cutaneous reactions to antidepressants. Am J Clin Dermatol 2002; 3: 329-39.
[8]
Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, et al. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J Clin Psychiat 2009; 70: 1258-65.
[9]
MacMorran WS, Krahn LE. Adverse cutaneous reactions to psychotropic drugs. Psychosomatics 1997; 38: 413-22.
[10]
Jick H. Adverse drug reactions: the magnitude of the problem. J Allergy Clin Immunol 1984; 74: 555-7.
[11]
Svensson C, Cowen E, Gaspari A. Cutaneous drug reactions. Pharmacol Rev 2000; 53: 357-79.
[12]
Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Adverse drug reactions. BMJ 1998; 316: 1295-8.
[13]
Valeyrie-Allanore L, Sassolas B, Roujeau J. Drug-induced skin, nail and hair disorders. Drug Saf 2007; 30: 1011-30.
[14]
Vervloet D, Durham S. Adverse reactions to drugs. ABC of allergies. Br Med J 1998; 316: 1511-4.
[15]
Bhattacharjee J, El-Sayeh H. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochr Database Syst Rev 2008; 3CD006617
[16]
Kimyai-Asadi A, Harris J, Nousari H. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999; 60: 714-25.
[17]
Adams BB, Mutasim DF. Pustular eruption induced by olanzapine, a novel antipsychotic agent. J Am Acad Dermatol 1999; 41: 851-3.
[18]
Raz A, Bergman R, Eilam O, et al. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 2001; 321: 156-8.
[19]
Warnock JK, Morris DW. Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol 2002; 3: 629-36.
[20]
Chang HY, Ridky TW, Kimball AB, et al. Eruptive xanthomas associated with olanzapine use. Arch Dermatol 2003; 139: 1045-8.
[21]
Latini A, Carducci M. Psoriasis during therapy with olanzapine. Eur J Dermatol 2003; 13: 404-5.
[22]
Jhirwal OP, Parsad D, Basu D. Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent. Int J Dermatol 2004; 43: 778-9.
[23]
Varghese ST, Balhara YP, Shyamsunder S, et al. Dermatological side effects of olanzapine. Ind J Med Sci 2005; 59: 320-1.
[24]
Duggal MK, Singh A. Arunabh, et al. Olanzapine-induced vasculitis. Am J Geriatr Pharmacoth 2005; 3: 21-4.
[25]
Christen S, Gueissaz F, Anex R, et al. Acute generalized exanthematous pustulosis induced by olanzapine. Acta Medica (Hradec Kralove) 2006; 49: 75-6.
[26]
Fernández-Torres R, Almagro M, Del Pozo M, et al. [Lichenoid drug eruption induced by olanzapine]. Actas Dermosifiliogr 2008; 99: 221-4.
[27]
Gregoriou S, Karagiorga T, Stratigos A, et al. Photo-onycholysis caused by olanzapine and aripiprazole. J Clin Psychopharmacol 2008; 28: 219-20.
[28]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
[29]
Eberlein-Konig B, Bindl A, Przybilla B. Phototoxic properties of neuroleptic drugs. Dermatology 1997; 194: 131-5.
[30]
Chignell CF, Motten AG, Buettner GR. Photo-induced free radicals from chlorpromazine and related phenothiazines: relationship to phenothiazine-induced photosensitization. Environ Health Perspect 1985; 64: 103-10.
[31]
Dutta H, Sengupta S, Tiwari RR. Olanzapine induced hyperpigmentation: a case report. Int J Pharm Sci Rev Res 2015; 31: 172-3.
[32]
Howanitz E, Pardo M, Losonczy M. Photosensitivity to clozapine. J Clin Psychiatry 1995; 56: 589.
[33]
Borovik AM, Bosch MM, Watson SL. Ocular pigmentation associated with clozapine. Med J Aust 2009; 190: 210-1.
[34]
Wickert WA, Campbell NR, Martin L. Acute severe adverse clozapine reaction resembling systemic lupus erythematosus. Postgrad Med J 1994; 70: 940-1.
[35]
Wolf J, Sartorius A, Alm B, Henn FA. Clozapine-induced lupus erythematosus. J Clin Psychopharmacol 2004; 24: 236-8.
